INTRODUCTION
Cancer cells are derived from normal precursors, which undergo a series of genetic alterations in successive clones of cells, resulting in uncontrolled proliferation and metastasis. Abnormal gene products synthesized by neoplastic cells can potentially generate novel tumor antigens. Appropriate stimulation of the immune system can induce a cell-mediated immune response directed against tumor antigens, and the transfer of inmunostimulatory genes into nonimmunogenic tumor cells can stimulate antitumor responses in animals that are protective against the nontransduced tumor cells upon rechallenge. We utilized direct gene transfer to introduce an allogeneic class I major histocompatibility complex (MHC) In this paper, we review the application of direct gene transfer to the study of vascular biology and its use for provision of immunotherapy in malignancy. Direct gene transfer with DNA liposome complex is less costly and time consuming than cell-mediated gene transfer. Moreover, the stability of liposome and DNA preparations and the ease with which they can be prepared and administered to recipients could facilitate their use in clinical therapy. 
METHODS OF DIRECT GENE DELIVERY

SITE-SPECIFIC GENE TRANSFER INTO VASCULAR CELLS IN W O
To introduce recombinant genes into specific target tissues in vim, we delivered retroviral vectors or DNA lipomme complexes to anatomically localized sites. Initially, vascular cells were transduced with recombinant genes in pipg, using retroviral vectors or DNA liposome complexes instilled into localized arterial segments. In a porcine model, a segment of the iliofemoral artery was isolated from the systemic circulation using a double balloon catheter. The space between the two balloons was flushed to remove residual serum, and a concentrated suspension of amphotropic Moloney murine leukemia viral vector or DNA liposome complexes was instilled in the arterial segment for thirty minutes prior to removal of the catheter. Recombinant gene expression was present in endothelial cells, vascular smooth muscle cells, and adventitial cells in arteries transduced with the marker gene fl-galactosidase. Recombinant gene expression decreased with time but was clearly present up to 21 weeks following retroviral gene transfer and was not detected in the downstream arterial segment or in other tissues by PCR analy~is.~ Intraarterial direct gene transfer can elucidare the pathologic response to recombinant growth factor gene expression in normal and injured arteries. The endothelial cell growth factor fibroblast growth factor-1 (FGF-1) induces endothelial cell proliferation in Pitm and is angiogenic in *. Because FGF-1 lacks a classical signal sequence, the study of its effects as an extracellular protein has been difficult. A chimeric gene, in which the signal sequence from the FGF-4 gene was fused to the coding sequence of FGF-1, was introduced directly into l o c a l i i segments of arteries in vim. This plasmid, complexed with Lipofectin@, was transfected into porcine arteries at low instillation pressure (150 mmHg) to minimize trauma to the vessel. Presence of the introduced DNA was confirmed 21 days after transfection by PCR, and protein expression was confirmed by immunohistochemisay. The secreted FGF-1 gene induced intimal proliferation, and in several vessels capillary formation was observed in the neointima.'* Such angiogenesis has been observed in atherosclerotic plaques; however, mechanisms to explain this observation have previously been lacking. Because of its effects as an angiogenic factor, this FGF-1 vector could potentially be useful to induce neovascularization of ischemic tissue following intravascular delivery into affected tissue.
Platelet-derived growth factor (PDGF) B chain has also been implicated in the generation of atherosclerosis. This growth factor is a potent mitogen for vascular smooth muscle cells, but does not induce proliferation of endothelial cells. To analyze the response to this growth factor in vivo, a plasmid expression vector encoding the human PDGF B gene was introduced into porcine arteries using Lipofectin@ at low instillation pressures. 19 The expression of introduced DNA was confirmed by PCR analysis of recombinant PDGF B mRNA. Immunohistochemistry revealed human PDGF BB protein expression in the intima and media but not in control arteries transduced with P-galactosidase. Quantitative morphometry of intimal and medial thickness demonstrated a sevenfold increase in the intimal-to-medical ratio compared to p-galactaidax-transduced vessels. Unlike the FGF-1-transduced arteries, the intimal thickening was not associated with neocapillary formation. These studies provide a method to examine the effects of recombinant growth factor gene expression on vascular physiology in normal and injured arteries. Such studies also provide a model to investigate inhibition of intimal proliferation using gowth factor or receptor antagonists.
To analyze the response of the immune system to a foreign protein expressed on endogenous vascular cells, a human MHC gene, HLA-B7, was introduced into the iliofemoral artery of pigs using retroviral vectors or DNA liposome complexes.23 Both vectors provided expression of HLA-B7 protein within vascular cells documented by PCR analysis of DNA and mRNA and by immunohistochemistry. Expression of the foreign histocompatibility antigen by vascular cells induced an intense inflammatory response in recipient animals, consisting of a mononuclear cell infiltrate in the adventitia and media. The inflammatory response was present by 1 1 days after gene transfer, peaked at 17 to 21 days, and had subsided by 75 days. Some neointimal thickening, as is seen following chronic inflammation, was noted in the transduced arteries. Further studies determined that cytotoxic T lymphocytes specific for the foreign antigen were generated in these animals. Control arteries transduced with the p-galactosidase gene did not develop inflammatory histologic changes or an immune response. The histologic and immunologic responses induced by HLA-B7 were similar for both retroviral and liposome-mediated gene transfer, confirming that each method can provide appropriate and biologically active gene expression. This study also demonstrated that expression of a single foreign MHC gene by normal cells could induce a significant localized immune response.
DIRECT GENE TRANSFER OF AUOGENEIC CLASS I MHC GENES INTO TUMORS
The induction of a specific cell-mediated response generated by intravascular transfer of a foreign class I MHC gene suggested that this approach could be applied to the immunotherapy of malignancy. Previous studies using cell-mediated gene transfer demonstrated that genetic modification of tumor cells can increase their immunogenicity and stimulate a specific antitumor response.2a38 To determine whether a therapeutic immune response could be generated against preexisting macroscopic tumors, we introduced an allogeneic class I MHC gene by intratumoral injection of DNA liposome complexes or retroviral vectors. MHC alleles are highly polymorphic, and most of the variation between alleles is concentrated in residues that comprise the peptide binding portion of the molecule.39 Consequently, transplanted tissue that expresses allogeneic MHC molecules is highly immunogenic, presumably due to the altered shape of the MHC in the peptide binding region. A high precursor frequency of CD8+ lymphocytes capable of reacting against allogeneic cells e x i~t s .~.~' Therefore, introduction of an allogeneic class I MHC gene into tumors should stimulate a strong immune response locally.
The murine class I MHC gene H-2K" was introduced into tumors in Pivo by direct intratumoral injection of a DNA liposome complex using DC-cholesterol liposomes. A weakly immunogenic murine tumor line CT26, a colon adenocarcinoma with the H-2d haplotype, was inoculated subcutaneously in BALB/c mice. Approximately 14 days later, when tumors were 5-8 mm in diameter, the tumors were transduced with the H-2Ks gene. Lymphocytes harvested from these animals 14 days after gene transfer demonstrated lytic activity against CT26 targets expressing H-2K". More importantly, cytotoxic lymphocytes reactive against the parental nontransduced CT26 cells were present, demonstrating the generation of an immune response to other tumor antigens. Injection of a control gene P-galactosidase complexed with the liposomes did not induce cytolytic T cells. Cytolytic activity against both transduced and parental tumor cells could be blocked by antibody against CD8+ but not CD4+ lymphocytes. This immune response was not protective in this rapidly growing murine tumor model because the tumors were relatively large at the time of gene transfer and grew progressively during the generation of the antitumor response. Experiments using intratumoral transfer of the P-galactosidase gene suggest that the efficiency of gene transfer was approximately 1%.
Significant attenuation of tumor growth and, in some cases, complete regression of existing tumors were achieved following H-2Ks gene transfer when mice were presensitized to the H-2K' gene. Mice were preimmunized against H-2Ks by intraperitoneal injection of either irradiated tumor cells expressing H-2Ks or of splenic lymphocytes from an H-2s mouse strain. Two histologic types of tumors, the colon adenocarcinoma CT26 and the fibrosarcoma MCA 106 from two different mouse strains, BALB/c, and C57BL/6, respectively, responded to tumor transduction with the H-2K" gene. This study demonstrated that the immunologic response to H-2Ks was not strain specific or tumor specific.
The antitumor response was mediated by T lymphocytes. The growth of CT26 or MCA 106 tumors in nude mice treated with the H-2K" gene was identical to that of P-galactosidase-treated mice or untreated controls. The immune response to H-2Ks gene transfer was abrogated by depletion of CD8+ T cells, but not by depletion of CD4+ cells. Direct gene transfer of the H-2Ks gene into the poorly immunogenic murine melanoma, B16BL6, in mice generated tumor-reactive lymphocytes in tumor-draining lymph nodes. When stimulated ex vivo with anti-CD3 mAb for two days followed by culture in low-dose IL-2 (10 U/ml) for three days, these effector cells had no direct cytolytic activity against B 16BL6 targets. However, adoptive transfer of these lymphocytes to mice bearing B16BL6 lung metastases resulted in a marked decrease in lung metastases in comparison to a control gene." These studies demonstrate that actively growing macroscopic tumors can be transduced with recombinant genes in vivo by intratumoral gene transfer using DNA liposome complexes. Moreover, an appropriate immunologic response can be generated against an allogeneic MHC protein expressed within actively growing tumors, and this strong immune response can stimulate a host immune response to weak tumor antigens. Appropriate augmentation of this antitumor immune response can mediate regression of preexisting tumors.
IMMUNOTHERAPY OF HUMAN MALIGNANCY BY DIRECT GENE TRANSFER PRECLINICAL TOXICITY ANALYSIS
To determine whether recombinant genes can be delivered safely in vivo using DNA liposome complexes, acute and long-term toxicity studies were performed in animal models. DC-cholesterol liposomes complexed with DNA were injected into mice intravenously or intratumorally, and the distribution of DNA was determined by PCR analysis of organs two to three weeks after gene transfer. The plasmid DNA was detected in heart and lung tissue in most cases and occasionally in kidney when mice received intravenous DNA liposome complexes. Intratumoral injection resulted in isolation of plasmid in tumor tissue and occasionally in heart, lung, and spleen. There were no histopathologic findings in the organs of any animals, including those containing plasmid DNA. In these instances, DNA was present at a very low level. Analysis of serum enzymes did not reveal evidence of liver, heart, or kidney dysfunction. Because of the finding of injected DNA in heart tissue, electrocardiography was performed during and after liposome injection. These electrocardiograms were all Expression of a foreign class I MHC gene on normal tissues could potentially induce autoimmunity. Mice that received the allogeneic MHC gene all generated a specific cytolytic T lymphocyte (CTL) response to the foreign gene product; however, there was no histopathologic or serologic evidence of organ t~xicity.~' It is likely that immunologic tolerance to normal tissue prevented immune mediated damage from the low levels of allogeneic gene expression in these tissues following intratumoral gene transfer. Intravenous, intraperitoneal, or subcutaneous injection of the allogeneic MHC gene complexed with liposomes did not induce a detectable pathology.
The potential for inadvertent modification of germ line tissue by recombinant gene is a concern for in vivo gene therapy. To address this question, 42 rabbits and pigs were treated with intravenous or intraarterial injection of DNA liposome complexes. Transfected DNA was never isolated from gonadal tissue by PCR, despite its presence in the transduced artery segments and occasionally in other organs.27 These studies demonstrate that direct gene transfer and expression of recombinant genes, including a foreign MHC gene, do not induce generalized autoimmunity to normal tissue, or detectable gene transmission to germ cells. Direct gene transfer using DNA liposome complexes therefore appeared suitable for human gene therapy.
DIRECT GENE THERAPY IN HUMAN CANCER
A phase I/II human gene therapy trial to provide immunotherapy for malignancy by direct intratumoral injection of an dogeneic MHC gene HLA-B7 complexed with DC-Chol liposomes was approved by the Recombinant DNA Advisory Committee in January l%U. 43 This protocol represents the first use of direct gene transfer into humans in mVo and is the first application of a nonviral vector-liposome-mediated gene transfer.& The stability of the DNA and liposomes coupled with the ease with which they can be reconstituted and administered to patients, provide the potential for such treatment to be provided in a generalized outpatient setting. Because most of the DNA is maintained extrachromosomally following liposome-mediated gene transfer, this approach would not provide permanent correction for genetic disorders in proliferating cells. However, repeated treatments might provide sustained correction of genetic diseases at sufficient levels to ameliorate symptoms. Applications of gene therapy to many acquired disorders or to provide immunotherapy for malignancy would require only transient expression of recombinant genes. Most gene therapy models and human protocols rely on modification of target cells m vim. This involves considerable effort and time, and the expense of large-scale dedicated tissue culture facilities. Additionally, m vivo gene transfer would not be applicable in situations where target cells fail to grow in culture, as commonly occurs with many somatic cells and neoplastic cells. Direct gene transfer into patients avoids many of the disadvantages of ex pivo gene therapy and minimiim delays in the initiation of treatment. Anatomically localized delivery of DNA liposome complexes directly into the parenchyma of tissues or through intravascular catheters into the vascular bed can provide site-specific expression of recombinant genes in pivo.
SUMMARY
Direct gene transfer has been used to develop molecular genetic interventions for acquired diseases in several animal models. Through the use of intravascular catheters or anatomically localized injection of DNA liposome complexes, specific tissues can be transduced with recombinant genes. Several promising applications of this method for the study of vascular biology have been demon- 
